

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 April 2017



Contents

Summary of decisions effective 1 April 2017.....	3
Section H changes to Part II	5
Index.....	8

Summary of decisions

EFFECTIVE 1 APRIL 2017

- Amino acid formula (without isoleucine, leucine and valine) (e.g. MSUD Maxamaid) powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can – to be delisted 1 May 2017
- Amiodarone hydrochloride (Lodi) inj 50 mg per ml, 3 ml ampoule – new listing and addition of HSS
- Amiodarone hydrochloride (Cordarone-X) inj 50 mg per ml, 3 ml ampoule – to be delisted 1 June 2017
- Aprepitant (Emend) cap 40 mg – new listing
- Auranofin tab 3 mg – restriction added and to be delisted 1 September 2017
- Benztropine mesylate tab 2 mg (Benztrop) and inj 1 mg per ml, 2 ml ampoule (Cogentin) – chemical name change
- Bupropion hydrochloride (Zyban) tab modified-release 150 mg – addition of HSS
- Clomifene citrate (Mylan Clomiphene and Serophene) tab 50 mg – chemical name change
- Darunavir (Prezista) tab 400 mg and 600 mg – price decrease and addition of HSS
- Erlotinib (Tarceva) tab 100 mg and 150 mg – amended restriction
- Fusidic acid (Fucidin) tab 250 mg – addition of HSS
- Granisetron (Granirex) tab 1 mg – to be delisted 1 October 2017
- Leflunomide (Apo-Leflunomide) tab 10 mg and 20 mg – new listing and addition of HSS
- Leflunomide (Arava) tab 10 mg and 20 mg – to be delisted 1 June 2017
- Levonorgestrel (Postinor-1) tab 1.5 mg – price increase and addition of HSS
- Naproxen tab long-acting 750 mg (Naprosyn SR 750), and tab long-acting 1 g (Naprosyn SR 1000) – new listing
- Prednisone (Apo-Prednisone) tab 1 mg, 2.5 mg, 5 mg and 20 mg – addition of HSS
- Protein supplement (Promod) powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can – delisted 1 April 2017
- Sodium chloride (Multichem) inj 0.9%, 20 ml ampoule – new listing
- Sodium chloride (InterPharma) inj 0.9%, 20 ml ampoule – HSS suspended
- Sumatriptan (Apo-Sumatriptan) tab 50 mg and 100 mg, 100 tab and 102 tab packs – new listing and addition of HSS

Summary of decisions – effective 1 April 2017 (continued)

- Sumatriptan (Arrow-Sumatriptan) tab 50 mg and 100 mg – to be delisted 1 June 2017
- Venlafaxine (Enlifax XR) cap 37.5 mg, 75 mg and 150 mg – new listing and addition of HSS
- Venlafaxine tab modified release 37.5 mg, 75 mg, 150 mg and 225 mg (Arrow-Venlafaxine XR) and cap modified release 37.5 mg, 75 mg and 150 mg (Efexor XR) to be delisted 1 June 2017
- Water (Multichem) inj 20 ml ampoule – new listing
- Water (InterPharma) inj 20 ml ampoule – HSS suspended

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 April 2017

BLOOD AND BLOOD FORMING ORGANS

40	SODIUM CHLORIDE (new listing) Inj 0.9%, 20 ml ampoule.....	5.00	20	Multichem
40	SODIUM CHLORIDE (HSS suspended) Inj 0.9%, 20 ml ampoule – 1% DV Mar-17 to 2019 31 Mar 2017	7.50	30	InterPharma
40	WATER (new listing) Inj 20 ml ampoule.....	5.00	20	Multichem
40	WATER (HSS suspended) Inj 20 ml ampoule – 1% DV Mar-17 to 2019-31 Mar 2017	7.50	30	Interpharma

CARDIOVASCULAR SYSTEM

44	AMIODARONE HYDROCHLORIDE (brand change) Inj 50 mg per ml, 3 ml ampoule – 1% DV Jun-17 to 2019	9.98	5	Lodi
	Note – Cordarone-X inj 50 mg per ml, 3 ml ampule to be delisted from 1 June 2017.			

GENITO-URINARY SYSTEM

61	LEVONORGESTREL (↑ price and addition of HSS) Tab 1.5 mg – 1% DV Jun-17 to 2019	4.95	1	Postinor-1
----	--	------	---	-------------------

HORMONE PREPARATIONS

67	PREDNISONE (addition of HSS) Tab 1 mg – 1% DV Jun-17 to 2020	10.68	500	Apo-Prednisone
	Tab 2.5 mg – 1% DV Jun-17 to 2020	12.09	500	Apo-Prednisone
	Tab 5 mg – 1% DV Jun-17 to 2020	11.09	500	Apo-Prednisone
	Tab 20 mg – 1% DV Jun-17 to 2020	29.03	500	Apo-Prednisone
68	CLOMIFENE CLOMIPHENE CITRATE (chemical name change) Tab 50 mg	29.84	10	Mylan Clomiphene Serophene

INFECTIONS

81	FUSIDIC ACID (addition of HSS) → Tab 250 mg – 1% DV Jun-17 to 2020	34.50	12	Fucidin
90	DARUNAVIR (↓ price and addition of HSS) → Tab 400 mg – 1% DV Jun-17 to 2020	335.00	60	Prezista
	→ Tab 600 mg – 1% DV Jun-17 to 2020	476.00	60	Prezista

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2017 (continued)

MUSCULOSKELETAL SYSTEM

99	AURANOFIN - Restricted: for continuation only (restriction added and delisting) Tab 3 mg Note – Auranofin tab 3 mg to be delisted from 1 September 2017.			
99	LEFLUNOMIDE (brand change) Tab 10 mg – 1% DV Jun-17 to 2020	2.90	30	Apo-Leflunomide
	Tab 20 mg – 1% DV Jun-17 to 2020	2.90	30	Apo-Leflunomide
	Note – Arava tab 10 mg and 20 mg to be delisted from 1 June 2017.			
108	NAPROXEN (amended pack size) Tab long-acting 750 mg – 1% DV Jun-15 to 2018	5.60	28	Naprosyn SR 750
	Tab long-acting 1 g – 1% DV Jun-15 to 2018	6.53	28	Naprosyn SR 1000
	Note – Naproxen tab 750 mg and 1 g pack size change from 90 pack bottle to 28 blister pack. The 90 tablet packs will be delisted at a later date.			

NERVOUS SYSTEM

109	BENZATROPINE BENZTROPINE MESYLATE (chemical name change) Tab 2 mg	7.99	60	Benztrop
	Inj 1 mg per ml, 2 ml ampoule.....	95.00	5	Cogentin
117	VENLAFAXINE (brand change) Cap 37.5 mg – 1% DV Jun-17 to 2020	6.38	84	Enlafax XR
	Cap 75 mg – 1% DV Jun-17 to 2020	8.11	84	Enlafax XR
	Cap 150 mg – 1% DV Jun-17 to 2020	11.16	84	Enlafax XR
	Note – Arrow-Venlafaxine XR tab modified release 37.5 mg, 75 mg, 150 mg and 225 mg, and Efexor XR cap modified release 37.5 mg, 75 mg and 150 mg to be delisted from 1 June 2017.			
123	APREPITANT (new listing) → Cap 40 mg.....	71.43	5	Emend
123	SUMATRIPTAN (brand change) Tab 50 mg – 1% DV Jun-17 to 2019	24.44	100	Apo-Sumatriptan
	Tab 100 mg – 1% DV Jun-17 to 2019	46.23	100	Apo-Sumatriptan
	Note – Arrow-Sumatriptan tab 50 mg and 100 mg to be delisted from 1 June 2017.			Apo-Sumatriptan
124	GRANISETRON (delisting) Tab 1 mg – 1% DV Jan-15 to 2017	5.98	50	Granirex
	Note – Granirex tab 1 mg to be delisted from 1 October 2017.			
134	BUPROPION HYDROCHLORIDE (addition of HSS) Tab modified-release 150 mg – 1% DV Jun-17 to 2020	11.00	30	Zyban

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 April 2017 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

142	ERLOTINIB (amended restriction – amended criteria shown only)		
	→ Tab 100 mg.....	764.00	30 Tarceva
	→ Tab 150 mg.....	1,146.00	30 Tarceva
	Restricted		
	Initiation		
	<i>Re-assessment required after 4 months</i>		
	All of the following:		
	1 Patient has locally advanced or metastatic, unresectable, non-squamous Non-Small Cell Lung Cancer (NSCLC); and		
	2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and		
	3 Either Any of the following:		
	3.1 Patient is treatment naive; or		
	3.2 Both:		
	3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and		
	3.2.2 Patient has not received prior treatment with gefitinib; or		
	3.2.3 Both:		
	3.2.1.3.1 The patient has discontinued gefitinib within 12 weeks of starting treatment due to intolerance; and		
	3.2.2.3.2 The cancer did not progress while on gefitinib; and		
	4 Erlotinib is to be given for a maximum of 3 months.		

SPECIAL FOODS

211	PROTEIN SUPPLEMENT (delisting)		
	→ Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can		e.g. <i>Promod</i>
	Note – Promod powder to be delisted from 1 April 2017.		
213	AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) (delisting)		
	→ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can		e.g. <i>MSUD Maxamaid</i>
	Note – MSUD Maxamaid to be delisted from 1 May 2017.		

Index

Pharmaceuticals and brands

A	
Amino acid formula (without isoleucine, leucine and valine)	7
Amiodarone hydrochloride.....	5
Apo-Leflunomide.....	6
Apo-Prednisone	5
Apo-Sumatriptan	6
Aprepitant	6
Auranofin	6
B	
Benzatropine mesylate	6
Benzotrop	6
Benztropine mesylate	6
Bupropion hydrochloride	6
C	
Clomifene citrate	5
Clomiphene citrate	5
Cogentin	6
D	
Darunavir	5
E	
Emend	6
Enlifax XR	6
Erlotinib	7
F	
Fucidin.....	5
Fusidic acid.....	5
G	
Granirex.....	6
Granisetron	6
L	
Leflunomide.....	6
Levonorgestrel	5
Lodi	5
M	
MSUD Maxamaid	7
Mylan Clomiphen	5
N	
Naprosyn SR 750.....	6
Naprosyn SR 1000.....	6
Naproxen	6
P	
Postinor-1.....	5
Prednisone.....	5
Prezista.....	5
Promod.....	7
Protein supplement	7
S	
Serophene	5
Sodium chloride.....	5
Sumatriptan	6
T	
Tarceva.....	7
V	
Venlafaxine	6
W	
Water	5
Z	
Zyban	6



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.